Recruiting EARLY_PHASE1 INTERVENTIONAL 2-arm NCT04048278

Lidocaine Infusion in Pancreatic Cancer

Lidocaine Infusion in Pancreatic Cancer: Translational Studies in a Preclinical Model And Human Subjects

Sponsor: University of Illinois at Chicago

Interventions Lidocaine Hydrochloride Saline Solution for Injection

Updated 9 times since 2019 Last updated: Feb 26, 2025 Started: Nov 8, 2018 Primary completion: Nov 8, 2025 Completion: Jan 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Pancreatic Cancer and is currently actively recruiting participants. University of Illinois at Chicago leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Jun 2025 — Present [monthly]

Recruiting EARLY_PHASE1
Apr 2025 — Jun 2025 [monthly]

Recruiting EARLY_PHASE1
Sep 2024 — Apr 2025 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Jan 2024 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

▶ Show 4 earlier versions

May 2022 — Jan 2024 [monthly]

Recruiting EARLY_PHASE1
Jun 2021 — May 2022 [monthly]

Recruiting EARLY_PHASE1
Jan 2021 — Jun 2021 [monthly]

Recruiting EARLY_PHASE1
Sep 2019 — Jan 2021 [monthly]

Recruiting EARLY_PHASE1

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Illinois at Chicago

Data source: University of Illinois at Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States